Weight-Loss Drugs Are Quietly Reshaping the Cannabis Market

What’s happening

GLP-1 weight-loss drugs (like semaglutide-based treatments) are changing how consumers use cannabis.

Users report reduced cravings and appetite, which is directly impacting cannabis consumption patterns, especially products linked to the “munchies” effect.

What’s changing / Business impact

• Cannabis companies are shifting toward lower-dose products and non-edible formats (vapes, tinctures)
• Slower digestion from GLP-1 drugs is altering how edibles are absorbed
• Early research suggests GLP-1 drugs may even help reduce substance dependency behaviors

Why this matters

This move signals that:

• A single drug class is now changing consumer behavior across industries
• Forcing adjacent markets to reposition products
• Creating second-order effects most companies don’t track

If you’re only watching your category, you’re missing where disruption actually starts.